Abstract
Cancer-testis (CT) antigens are immunogenic proteins expressed in normal gametogenic tissues and in different types of tumors. CTSP-1 is a CT antigen frequently expressed in prostate tumors, and capable of eliciting humoral response in prostate cancer patients. Here, we analyzed the presence of anti-CTSP-1 antibodies in 147 patients with localized prostate cancer and determined its prognostic value for predicting biochemical-recurrence after radical prostatectomy. Anti-CTSP-1 antibodies were detected in 25% of the patients and a significant correlation (p = 0.017) between CTSP-1 protein expression and the presence of specific humoral response was observed. No association was found between the presence of antibodies and the pathological variables analyzed. On univariate analysis, patients without antibodies against CTSP-1 had a lower biochemical-recurrence free survival than did those with anti-CTSP-1 antibodies, although the difference between the groups was not statistically significant (57 vs. 75%, p = 0.075). However, the presence of antibodies against CTSP-1 was significantly associated with a better prognosis in patients with higher Gleason score (36 vs. 80%, p = 0.028). On multivariate analysis, antibodies against CTSP-1 ...Continue Reading
References
Mar 1, 1992·Human Pathology·D F Gleason
Jun 17, 1998·International Journal of Cancer. Journal International Du Cancer·B LethéT Boon
Sep 28, 1998·JAMA : the Journal of the American Medical Association·P C AlbertsenM J Barry
Aug 13, 2002·Expert Opinion on Biological Therapy·Bela Bodey
Nov 26, 2002·Immunological Reviews·Matthew J ScanlanYao-Tseng Chen
Apr 6, 2004·The Prostate·Alexander FossåErlend B Smeland
Aug 17, 2004·Immunity·Gavin P DunnRobert D Schreiber
Aug 18, 2004·The Journal of Urology·Kimberly A RoehlWilliam J Catalona
Oct 2, 2004·Aktuelle Urologie·L PriklerH-P Schmid
Jan 8, 2005·Clinical Prostate Cancer·Jonathan L Chin, Robert E Reiter
Apr 6, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·David I QuinnRobert L Sutherland
Jul 22, 2005·Nature Reviews. Cancer·Andrew J G SimpsonLloyd J Old
Nov 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W Scott WebsterEugene D Kwon
Feb 10, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Catherine BarrowJonathan Cebon
Mar 4, 2006·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Mar 22, 2006·Expert Opinion on Biological Therapy·Anil Suri
Apr 25, 2006·Current Urology Reports·Lawrence Fong, Eric J Small
Jun 9, 2006·Diagnostic Pathology·A BuhmeidaY Collan
Nov 23, 2006·Proceedings of the National Academy of Sciences of the United States of America·Raphael B ParmigianiAnamaria A Camargo
Citations
Jun 20, 2012·Nature Reviews. Urology·Prakash KulkarniRobert H Getzenberg
Aug 30, 2008·BMC Cancer·Sergei RudchenkoIlya Trakht
Jun 30, 2009·Cancer Immunology, Immunotherapy : CII·Miriam ReuschenbachNicolas Wentzensen
Aug 28, 2012·Cancer Letters·Qiang ShanSiqi Liu
Jan 15, 2011·Clinical & Developmental Immunology·Sebastian KoboldDjordje Atanackovic
May 4, 2010·Human Immunology·Sebastian KoboldDjordje Atanackovic
Aug 5, 2010·Archives of Medical Research·Soudeh Ghafouri-FardMohammad Hossein Modarressi
May 12, 2016·Biomarkers in Cancer·Pierre-Olivier GaudreauFred Saad
Oct 4, 2017·Immunotherapy·Sepideh Faramarzi, Soudeh Ghafouri-Fard
Mar 3, 2015·Expert Review of Clinical Immunology·Vladimír Vonka, Martina Petráčková
Apr 23, 2019·Human Antibodies·Maliheh AstanehZahra Taherian Esfahani
Jan 3, 2020·Critical Reviews in Clinical Laboratory Sciences·Majid Ghayour-MobarhanMeysam Moghbeli